Loading...
Britannia Life Sciences Inc.
BLAB.CN•CNQ
Healthcare
Biotechnology
CA$0.07
CA$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $1.81M in Q3 2023 to $1.96M in Q2 2024. Gross profit continued to perform well, with margins at 67% in the latest quarter. Operating income reached $343986.00 in Q2 2024, holding a steady 18% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$558272.00. Net income dropped to -$1.19M, keeping EPS at -$0.007. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan